Alterola Biotech Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Alterola Biotech Inc Announces Changes In Registrant’s Certifying Accountant-Form 8-K
Alterola Biotech Inc reported in its Form 8-K that on July 15, 2013, De Joya Griffith & Company, LLC (the Former Accountant) was dismissed as the Company’s accountant. The Company has engaged Silberstein Ungar, PLLC (New Accountant) as its principal accountants effective July 15, 2013. The decision to change accountants was approved by the Company’s board of directors. The Former Accountant’s audit reports on the financial statements of the Company for the period from inception (July 21, 2008) to September 30, 2010 contained no adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit reports on the financial statements of the Company for the period from inception (July 21, 2008) to September 30, 2010 contained an uncertainty about the Company’s ability to continue as a going concern. During the period from inception (July 21, 2008) to September 30, 2010, and through the interim period ended July 15, 2013, there were no disagreements (as such term is defined in Item 304 of Regulation S-K) with the Former Accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for such periods.
Latest Developments for Alterola Biotech Inc
Latest Key Developments in Pharmaceuticals
- RaQualia Pharma Inc expecx extraordinary profit for Q4 of FY 2013
- Lanzhou Foci Pharmaceutical Co Ltd appoints Li Yunpeng Chairman
- Celldex Therapeutics Inc's CDX-301 in combination with Mozobil increases hematopoietic stem cell mobilization and results in improved transplantation of mobilized cells in preclinical studies
- Share this
- Digg this